Tigermed
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tigermed - overview
Established
2004
Location
Hangzhou, Zhejiang, China
Primary Industry
Healthcare
About
Founded in 2004 and based in Hangzhou, China, Hangzhou Tigermed Consulting Company Limited, trading as Tigermed, operates as a contract research organization that provides enterprises with regulatory processing, clinical research, biometrics, and medical translation services. The company has set up more than 100 subsidiaries. The co-founder as well as the CEO of the company, Xiaoping Ye, worked at Squibb Pharmaceuticals. Tigermed has over 10,000 employees and 29 overseas branches in Singapore, Malaysia, Indonesia, UK, Canada and other countries.
In August 2020, the company was listed on Hong Kong Stock Exchange. Tigermed provides a full range of services including Phase I-IV clinical trials, registration, data management and statistical analysis, and medical translation. The services offered by the company can be used in all types of pharmaceutical products, including drugs, medical devices, diagnostic reagents and health food and can be used in therapeutic areas of hepatitis and oncology. The company's revenue is generated by providing services such as Phase I-IV clinical trials, registration applications, data management and statistical analysis, and medical translation for various pharmaceutical products including drugs, medical devices, diagnostic reagents, and health foods.
The company will further improve the delivery and service systems and will recruit the CRO personnel.
Current Investors
Lake Bleu Capital, Qiming Venture Partners
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Epidemiology, Oncology/Cancer Treatment, Diagnostic Equipment, Pharmaceutical Research & Development
Website
www.tigermed.net/
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Tigermed - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 252,758,150.1 | 331,528,356.6 | 610,681,731.5 | 912,123,878.8 | 1,162,046,728.9 | 1,646,306,694.3 | 2,298,030,160.7 | 2,793,154,006.8 | 3,176,233,864.2 | - | - | - |
| % Revenue Growth (YoY) | - | 31.2% | 84.2% | 49.4% | 27.4% | 41.7% | 39.6% | 21.5% | 13.7% | - | - | - |
| EBITDA (USD) | 71,023,617.4 | 94,923,148.5 | 174,474,628.9 | 241,072,572.2 | 234,168,762.3 | 461,032,383.2 | 664,445,800 | 1,141,455,885.6 | 2,460,619,178.6 | - | - | - |
| Operating Income (USD) | 66,727,020.7 | 89,888,473.2 | 161,673,120.8 | 209,024,154.5 | 197,556,191.8 | 428,482,349.9 | 603,244,025.7 | 1,094,204,671.3 | 2,310,363,546.8 | - | - | - |
| Operating Margin | 26.4% | 27.1% | 26.5% | 22.9% | 17.0% | 26.0% | 26.3% | 39.2% | 72.7% | - | - | - |
| % EBITDA Margin | 28.1% | 28.6% | 28.6% | 26.4% | 20.2% | 28.0% | 28.9% | 40.9% | 77.5% | - | - | - |
| NET Income (USD) | 67,826,174.1 | 94,747,420.4 | 136,395,256.2 | 173,891,457.4 | 156,780,727.9 | 332,173,166.6 | 506,797,168.2 | 975,322,356.7 | 2,029,000,733.3 | - | - | - |
| % Net Margin | 26.8% | 28.6% | 22.3% | 19.1% | 13.5% | 20.2% | 22.1% | 34.9% | 63.9% | - | - | - |
Tigermed - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | Tigermed | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.